Exenatide in the treatment of type 2 diabetes: a health technology assessment

Xin-chun GU,Peng MEN,Suo-di ZHAI
2018-01-01
Abstract:Objective: To evaluate the effectiveness, safety and economy of the clinical use of exenatide, providing evidence for physicians and decision makers. Methods: Pub Med, EMbase, Cochrane Library and CNKI were systematically searched. Two reviewers independently identified RCTs and cost-effectiveness studies according to the inclusion criteria, extracted data and assessed quality of included studies. Qualitative analysis and metaanalysis were performed. Results: Among 5 828 screened articles, 26 RCTs and 11 cost-effectiveness analysis were included. In type 2 diabetes patients, HAb1 c level was significantly reduced in exenatide group than in OADs (oral anti-diabetic drug) group [WMD-1. 04%, 95% CI (-1. 26 to-0. 81), P<0. 000 01], while there was no effect compared with insulin group. Exenatide could reduce body weight [OADs: WMD-1. 27 kg, 95% CI (-1. 60 ~-0. 94), P<0. 000 01; insulin: WMD-4. 59 kg, 95% CI (-5. 41 ~-3. 76), P<0. 000 01]and also reduced the risk of hypoglycemia, but at the same time increased the risks of nausea, vomit and diarrhea when compared with OADs or insulin. Exenatide cotreatment with insulin glargine could improve patients ' QALYs andhave cost effective. Conclusion: Exenatide was an efficacious and safe choice for type 2 diabetes treatment and is a cost-effectiveness option.
What problem does this paper attempt to address?